



Published in final edited form as:

*Methods Enzymol.* 2020 ; 641: 373–399. doi:10.1016/bs.mie.2020.03.009.

## Enzymatic covalent labeling of RNA with RNA transglycosylation at guanosine (RNA-TAG)

Kayla N. Busby,

Neal K. Devaraj\*

Department of Chemistry and Biochemistry, University of California, San Diego, CA, United States

### Abstract

Technologies for the labeling, detection, and manipulation of biomolecules have drastically improved our understanding of cell biology. As the myriad of functional roles for RNA in the cell are increasingly recognized, such tools to enable further investigation of RNA are the subject of much interest. RNA-TAG is an enzymatic method for site-specific, covalent labeling of RNA. This methodology makes use of a bacterial tRNA modifying enzyme, tRNA guanine transglycosylase, to incorporate modified substrate analogs into a target RNA, resulting in highly efficient and site-specific RNA labeling. In this chapter, we introduce the underlying principles of the RNA labeling reaction, discuss various applications of RNA-TAG, and present protocols for labeling specific RNA transcripts using this system.

### 1. Introduction

Once overlooked as a transient messenger between DNA and protein, the role of RNA as an important functional molecule in cell biology has been increasingly recognized. Cellular functions not only rely on the production of canonical ribosomal RNA (rRNA), transfer RNA (tRNA) and messenger RNA (mRNA) molecules, but also functional small nuclear RNAs (snRNAs), microRNAs (miRNAs), and long noncoding RNAs (lncRNAs) (Cech & Steitz, 2014; Cooper, Wan, & Dreyfuss, 2009). Furthermore, the complexity of mammalian mRNAs has emerged as an important aspect of gene regulation and expression, with complex networks of RNA-protein interactions controlling mRNA stability, localization, and expression (Singh, Pratt, Yeo, & Moore, 2015). This growing interest in RNA biology has spurred the demand for new tools to enable further investigation of RNA structure and function.

Functional characterization of biomolecules through their direct conjugation to small molecule probes has proven to be an extremely effective strategy. For example, various methodologies have been developed for protein labeling, enabling advances in our understanding of protein structure and function. These strategies include the use of amine-reactive handles as well as enzymatic labeling approaches, such as SNAP-TAG and other self-labeling proteins, among others (Chen, Howarth, Lin, & Ting, 2005; Gautier et al.,

\*Corresponding author: ndevraj@ucsd.edu.

2008; Ho & Tirrell, 2016). While numerous robust tools exist for protein labeling, few tools exist for the site-specific covalent modification of RNA. A commonly used approach employs T4 ligase for 3' end-labeling with various fluorophores or biotin (Richardson & Gumpert, 1983). Recently, other enzymatic methods based on RNA modifying enzymes have been developed. For example, the methyltransferase Tgs has been engineered to enable labeling of the 5' cap of mRNAs (Schulz, Holstein, & Rentmeister, 2013). Another approach used an archaeal tRNA modifying enzyme to enable labeling of tRNA or RNAs encoding a complete tRNA sequence with an amine-reactive handle (Li et al., 2015). In this chapter, we discuss the use of a bacterial RNA modifying enzyme to label a small, encodable hairpin structure within an RNA of interest using a method called RNA-transglycosylation at guanosine (RNA-TAG). The advantages of this approach include its specific recognition of a unique small molecule nucleobase analog, the ability to directly add functional groups without the need for secondary click reactions, as well as its recognition of a short, 17-nucleotide stem loop that can be encoded at any site within the RNA of interest.

### 1.1 RNA labeling with RNA-TAG

RNA transglycosylation at guanosine (RNA-TAG) is a technology for RNA labeling that leverages a bacterial tRNA guanine transglycosylase (TGT) enzyme to covalently label an RNA of interest with a small molecule probe (Alexander, Busby, Cole, Zhou, & Devaraj, 2015). In order to achieve this labeling, derivatives of the bacterial small molecule substrate, preQ<sub>1</sub>, are utilized. A TGT recognition element, consisting of a short ( 17 nucleotide) hairpin that mimics the anticodon stem loop of its native tRNA substrates, is encoded into the RNA of interest in order to facilitate TGT labeling (Fig. 1). In the sections below, substrate recognition by TGT will be discussed. While much crystallographic evidence has been collected using *Zymomonas mobilis* (*Z. mobilis*) TGT, *E. coli* TGT numbering will be used, as this enzyme has been, to date, used more extensively with RNA-TAG.

### 1.2 RNA modification by tRNA guanine transglycosylase

The tRNA guanine transglycosylases (TGTs) are a well-characterized class of enzymes that are found in archaea, eubacteria and eukaryotes. While most RNA post-transcriptional modifications occur through chemical modification of an existing nucleoside, TGTs are extraordinary in their catalysis of transglycosylation reactions. Bacterial and eukaryotic TGTs recognize and modify four tRNAs, namely tRNA<sup>Asn</sup>, tRNA<sup>Asp</sup>, tRNA<sup>Tyr</sup>, and tRNA<sup>His</sup>, by exchanging a guanine at the wobble position of the anticodon stemloop with a 7-deazaguanine derivative. Bacterial TGTs introduce preQ<sub>1</sub> into the tRNA substrate, which is then enzymatically transformed to the hypermodified base queuine. In contrast, eukaryotic TGTs modify their cognate tRNAs directly with queuine that has been salvaged from the environment (Fig. 2). Despite the conservation of queuine modification across kingdoms, its functional role is not fully understood. Previous studies have established potential contributions to invasion and proliferation in bacteria, ribosomal frameshifting in viruses, and roles in development, proliferation, metabolism, cancer, and tyrosine biosynthesis in eukaryotes (Fergus, Barnes, Alqasem, & Kelly, 2015).

TGTs are also observed in archaea, though their function differs significantly from bacterial and eukaryotic TGTs. Sharing approximately 20–25% of sequence identity with bacterial

TGTs, archaeal TGTs recognize and modify position 15, a site within the D-arm in the majority of tRNAs (Stengl, Reuter, & Klebe, 2005). An alternative nucleobase, preQ<sub>0</sub>, is inserted, which is further modified to form archaeosine; it is thought that this modification stabilizes tRNA structure at high temperatures (Gregson et al., 1993).

### 1.3 RNA recognition by bacterial TGT

Previous biochemical studies of *E. coli* TGT have established that the entire tRNA structure is not required for recognition of an RNA substrate. Curnow and coworkers initially identified that ECY-A1, a truncated 17 nucleotide RNA hairpin derived from the anticodon stem loop of tRNA<sup>Tyr</sup>, was recognized by *E. coli* TGT (Curnow, Kung, Koch, & Garcia, 1993). Extension of this RNA hairpin by 4 base pairs (ECYMH) was found to improve reaction kinetics at 37 °C, most likely due to increased thermal stability (Curnow & Garcia, 1995). RNA mutational studies of truncated hairpins have demonstrated the importance of the U<sup>33</sup>G<sup>34</sup>U<sup>35</sup> loop sequence (Table 1) (Curnow & Garcia, 1995; Nakanishi et al., 1994).

Crystallographic studies of bacterial TGT derived from *Z. mobilis* in complex with a hairpin RNA substrate have also provided insight into how TGT recognizes its RNA substrate (Xie, Liu, & Huang, 2003). In agreement with the biochemical data, conserved interactions are observed with U<sup>35</sup> and G<sup>34</sup> nucleobases. With respect to U<sup>35</sup>, Arg286 donates two hydrogen bonds to O2, and Arg289 donates a hydrogen bond to O4. Further interactions such as a cation- $\pi$  interaction with Lys52 and hydro-phobic interactions with Val282 strengthen recognition of U<sup>35</sup>. U<sup>33</sup> also makes hydrogen bonding interactions with Lys264 and Asp267. However, these residues are not strictly conserved, and it was hypothesized that instead, U<sup>33</sup> plays an important role in the formation of an unusual zig-zag conformation in the loop region. Because there are few base-specific interactions between TGT and its RNA substrate, this conformational change is necessary for optimal binding of TGT through surface and charge complementarity. Crystallographic evidence has also supported the functional significance of a TGT homodimer, where the first unit is catalytic and the second unit plays a role in recognition and proper orientation of the bound tRNA (Stengl et al., 2007).

In order to target an RNA of interest for TGT-mediated labeling, it is necessary to encode an RNA substrate into that RNA of interest. Due to its short (17 nucleotide) length, the ECY-A1 hairpin has been most commonly used; an unstructured spacer is typically used on either side of the hairpin to promote proper folding of the target hairpin (Alexander et al., 2015; Ehret, Zhou, Alexander, Zhang, & Devaraj, 2018; Zhang, Zhou, Busby, Alexander, & Devaraj, 2018; Zhou, Alexander, & Devaraj, 2017). The extended hairpin, ECYMH, has also been successfully utilized, and may be preferred to increase labeling efficiency. Based on the previous literature, it is likely that other RNA hairpin structures, containing the “UGU” sequence and capable of assuming the appropriate binding conformation, may also serve as potential substrates.

### 1.4 Nucleobase recognition and catalytic mechanism

More than 170 RNA modifications have been identified in nature, with most modifications carried out through enzymatic functionalization of existing nucleobases (Frye, Haranda,

Behm, & He, 2018). TGTs are therefore unusual in their removal and replacement of a nucleobase with a different, functionalized, nucleobase, making them an excellent candidate for catalyzing RNA labeling with synthetic analogs. The mechanism of catalysis by bacterial TGT has been studied extensively, and has been shown to follow a ping-pong mechanism (Fig. 3) (Goodenough-Lashua & Garcia, 2003). A highly conserved catalytic aspartate residue (Asp264) acts as a nucleophile to break the glycosidic linkage of the guanosine, forming a TGT-RNA covalent intermediate (Xie et al., 2003). Exchange of the excised guanine in the binding pocket for preQ<sub>1</sub> then allows for nucleophilic attack of the ribose by N9 of preQ<sub>1</sub>, reforming a glycosidic bond. While TGT can catalyze the reversible exchange of guanine, insertion of preQ<sub>1</sub> is irreversible (Farkas, Jacobson, & Katze, 1984).

The binding pocket of TGT responsible for nucleobase recognition has been studied extensively through biochemical and crystallographic studies. Asp89 is a strictly conserved residue involved in recognition of guanine through hydrogen bonding at N2; it is also thought to play a role as a general base in catalysis (Xie et al., 2003). Asp143 plays a key role in recognizing the Watson-Crick face of guanine and preQ<sub>1</sub> through hydrogen bonding interactions to N1 and N2 (Todorov & Garcia, 2006; Todorov, Tan, Nonekowski, Garcia, & Carlson, 2005). Additional interactions with Ser99, Gln187, and the backbone of Gly214 also contribute to binding of guanine (Stengl et al., 2005; Xie et al., 2003). PreQ<sub>1</sub> recognition is mediated through hydrogen bonding interactions of the carbonyl group in the Leu215/Ala216 peptide bond with the aminomethyl moiety of preQ<sub>1</sub>, which is most likely in a protonated form at physiological pH (Hoops, Park, Garcia, & Townsend, 1996). It has been hypothesized that this amide bond changes conformation, to present either the NH or carbonyl functionality for hydrogen bonding, to mediate alternative binding of guanine and preQ<sub>1</sub> (Stengl et al., 2005). This conformational change, mediated by Glu219 in bacterial TGT, can explain the differential substrate specificities of archaeal TGTs. In crystal structures of the archaeal TGT from *Pyrococcus horikoshii*, this peptide bond is only observed in the NH-presenting form, consistent with its recognition of preQ<sub>0</sub> instead of preQ<sub>1</sub> (Ishitani et al., 2002, 2003). Recent biochemical and structural studies of human TGT have also uncovered the basis for the preferential recognition of queuine in eukaryotic systems. The substitution of Val217 for a glycine in human TGT enlarges the binding pocket, allowing for the binding of the cyclopentadiol moiety of queuine (Johannsson, Neumann, & Ficner, 2018). Based on biochemical evidence, it also seems likely that Cys145, which is replaced with a valine in human TGT, plays a role in the differential nucleobase recognition (Chen et al., 2011).

Structure-activity studies examining the recognition of preQ<sub>1</sub> have shown that there is a strong impact of the aminomethyl group on bacterial TGT binding affinity (Hoops, Townsend, & Garcia, 1995). While native substrates lacking the aminomethyl substituent, such as guanine and preQ<sub>0</sub>, are recognized with only a slightly reduced binding affinity (5–6-fold), other 7-deazaguanine derivatives have dramatically reduced binding (Table 2). This evidence suggests that the exocyclic amine plays a large role in bacterial TGT recognition of preQ<sub>1</sub>, which is further supported by the crystallographic evidence of hydrogen bonding of this group with the peptide backbone (Xie et al., 2003). Because the pK<sub>a</sub> of preQ<sub>1</sub>'s exocyclic amine is in the range of 10 (Hoops et al., 1996), it is likely that this amine is protonated at physiological pH, and it has been postulated that charge-assisted binding

is also possible (Stengl & Klebe, 2007). Thus, successful preQ<sub>1</sub> substrates for use with RNA-TAG have all been modified through alkylation of this exocyclic amine. Both PEG and alkyl linkers have been utilized to append various probes to the preQ<sub>1</sub> scaffold, with the use of an alkyl linker improving both binding affinity and enzyme turnover significantly (Zhou et al., 2017). A variety of probes, including BODIPY, Cy5, Cy7, thiazole orange, biotin, photocleavable groups, and tetrazine, have been successfully incorporated into RNA by appending them to preQ<sub>1</sub> in this manner.

### 1.5 Key differences in TGT systems for applications in mammalian models

RNA contributes greatly to the complexity of eukaryotic systems, with various controls of gene expression including alternative splicing, polyadenylation, protein binding sites, and microRNAs; therefore, many potential applications of RNA-TAG include its use in the context of mammalian cells. Accordingly, it is important to consider the ways in which bacterial and eukaryotic TGT modifications compare in order to understand where its use may be appropriate. As previously discussed, the small molecule selectivity for bacterial and mammalian TGTs differ; preQ<sub>1</sub> is the preferred substrate for bacterial TGT, while queuine is the preferred substrate for mammalian TGT (Table 3) (Chen et al., 2011). Furthermore, while it has been shown that a minimal stem loop substrate is accepted by bacterial TGTs, the mammalian TGT requires the full tRNA structure for recognition (Grosjean, Edqvist, Stråby, & Giegé, 1996).

Importantly, preQ<sub>1</sub> and queuine modification is irreversible, so queuine-modified tRNA present in mammalian systems would not be expected to be a substrate for further modification by TGTs (Biela et al., 2013; Farkas et al., 1984). Mitochondrial tRNAs have also been found to be queuine-modified (Suzuki & Suzuki, 2014). However, in certain cancer cells, it has been shown that tRNA is under-modified by queuine; therefore optimization may be necessary for use in these cells (Pathak, Jaiswal, & Vinayak, 2005). Furthermore, queuine modification is not observed in yeast tRNAs (Walden, Reyniers, Hiatt, & Farkas, 1982). Studies by our lab have shown that, in *E. coli* cells that have a deletion of a key preQ<sub>1</sub> biosynthetic enzyme (QueC), treatment with preQ<sub>1</sub>-biotin allows for the labeling and enrichment of tRNA, presumably through the expression of native *E. coli* TGT (data not shown). Accordingly, there may be potential applications of this technology in the study of tRNA and tRNA modifications in some systems.

### 1.6 Applications

RNA-TAG has been utilized in a variety of contexts, demonstrating its utility in both the study and manipulation of RNA in biological systems. These applications include fixed cell RNA imaging, affinity purification of RNA, control of translation in mammalian cells, and labeling of modified RNA (modRNA) for therapeutic applications.

The localization of RNA within cells is a key aspect of gene expression that is highly regulated in complex organisms, and the misregulation of RNA localization has been implicated in various neurological and muscle disorders (Chin & Lécuyer, 2017). Fixed cell imaging of RNA is a commonly utilized tool, especially with the popular fluorescence in situ hybridization (FISH) technique. Using RNA-TAG, the direct labeling and imaging of

an RNA of interest has been demonstrated using a variety of fluorophores, including Cy7, BODIPY, and thiazole orange derivatives (Alexander et al., 2015; Zhou et al., 2017). In these studies, the targeted RNA (mCherry) was expressed with the ECY-A1 sequence, or “TAG,” appended in the 3' UTR. This mCherry-TAG transcript could be successfully labeled by treating formaldehyde-fixed CHO cells with *E. coli* TGT enzyme and the appropriate preQ<sub>1</sub>-fluorophore derivative. Importantly, controls that lacked the mCherry-TAG transcript, or lacked treatment with *E. coli* TGT, showed much lower levels of fluorescence. These results indicate that the desired mCherry-TAG transcript was labeled selectively by *E. coli* TGT, even in the presence of other mammalian RNA species, such as tRNA (Alexander et al., 2015). This technique was further advanced by the development of fluorogenic preQ<sub>1</sub>-thiazole orange derivatives, in which the bulky substituents reduced the intercalating abilities of thiazole orange such that fluorescence was increased upon covalent incorporation by TGT, thus allowing wash-free imaging (Zhou et al., 2017). In addition, affinity purification of RNA has been demonstrated by labeling an RNA of interest with preQ<sub>1</sub>-biotin, also in the presence of total RNA from CHO cells (Alexander et al., 2015).

RNA-TAG has also been applied to the manipulation of RNA within mammalian cells, specifically through light-activated control of translation (Zhang et al., 2018). PreQ<sub>1</sub> derivatives bearing a coumarin-based photocleavable linker were used to label TGT recognition elements in the 5' UTR of a capped, polyadenylated RNA of interest. This labeled, mature mRNA was transfected into HeLa cells, and reduced protein production was observed in RNAs labeled with the photocleavable group. Furthermore photoirradiation, which is expected to cleave the photocleavable group, allowed for the activation of translation in these cells.

This method has also been shown to tolerate modified RNA (modRNA) transcripts. Several RNA modifications, such as 5-methylcytosine (5-mC) and pseudouridine (Ψ), have been shown to increase RNA stability, decrease immune response, and increase the translation capacity of RNAs (Karikó et al., 2008; Uchida, Kataoka, & Itaka, 2015); these attributes make modRNA a useful tool for RNA gene therapy approaches. Using RNA-TAG, RNA transcripts with these modified nucleobases could be labeled with high efficiencies (Ehret et al., 2018). Furthermore, the use of preQ<sub>1</sub>-tetrazine, which could then be used in subsequent tetrazine-mediated click chemistry, was also demonstrated (Ehret et al., 2018).

The broad scope of applications possible with RNA-TAG demonstrates the breadth and robustness of this labeling technique. A variety of probes, including fluorophores, biotin, click handles, and even photocleavable functionalities can be incorporated into an RNA of interest with high levels of efficiency. The observed selectivity and high efficiencies of this reaction indicate the potential for this technique to be utilized as a tool in various areas of RNA biology.

## 2. Method

### 2.1 Definition

Enzymatic covalent labeling of RNA with RNA transglycosylation at guanosine (RNA-TAG).

## 2.2 Rationale

Few methods exist for the enzymatic, site-specific labeling of RNA. While other approaches allow labeling at the 5' or 3' ends of RNA, or labeling of large encodable structures, RNA-TAG enables the labeling of an RNA transcript bearing a short stem loop sequence. Furthermore, RNA-TAG utilizes a unique nucleobase substrate, preQ<sub>1</sub>, to which probes can be directly attached for enzymatic incorporation into the RNA of interest. The protocols below describe the various biochemical methods needed to execute labeling of a transcript using this technique, including expression and purification of the TGT enzyme, cloning of a plasmid to transcribe an RNA with an appended TAG sequence, and carrying out the labeling reaction.

## 2.3 Materials, equipment and reagents

### Expression and purification of *E. coli* TGT

Ultra-pure water, nuclease free

Bacterial expression plasmid encoding *E. coli* TGT (TGT-His, Addgene ID 138201)

BL21 (DE3) competent cells (New England Biolabs)

Phenylmethylsulfonyl fluoride (PMSF)

Tris base ([Tris\(hydroxymethyl\)aminomethane](#))

Tris hydrochloride

NaCl

HEPES sodium salt

HEPES

Dithiothreitol (DTT)

500 mM EDTA, pH 8.0, nuclease free (Invitrogen)

HisPur™ Ni-NTA Spin Purification Kit, 0.2 mL (Thermo Scientific)

Dialysis cassettes (Slide-a-lyzer MINI, 20 kDa, Thermo Scientific)

Incubator-shaker

Refrigerated microcentrifuge

Probe sonicator

### Construction of an RNA expression construct with a TGT recognition element

Ultra-pure water, nuclease free

Plasmid for transcription of RNA with TAG recognition element (pcDNA3.1-(empty)-TAG, Addgene ID 138209)

Isolated total RNA, human (alternatively, Universal Human Reference RNA, Agilent)

Oligos for RT-PCR amplification of the desired RNA sequence, with flanking restriction sites (examples given in text)

dNTP mix, 10 mM each (Invitrogen)  
Maxima reverse transcriptase (Thermo Scientific)  
RNase inhibitor, murine (New England Biolabs)  
Q5 high fidelity 2 × master mix (New England Biolabs)  
PCR cleanup kit (QIAquick PCR cleanup, Qiagen)  
*NheI*-HF (New England Biolabs)  
BamHI-HF (New England Biolabs)  
Antarctic phosphatase (New England Biolabs)  
T4 ligase (New England Biolabs)  
DH5α competent cells (New England Biolabs)  
Thermocycler

#### RNA labeling with RNA-TAG

Ultra-pure water, RNase free  
Labeled preQ<sub>1</sub> derivative (discussed in Section 2.5)  
RNA transcript bearing TGT recognition element  
Expressed *E. coli* TGT enzyme  
HEPES sodium salt  
HEPES  
Dithiothreitol (DTT)  
Magnesium chloride, hexahydrate  
RNase inhibitor, murine  
100% ethanol  
3 M sodium acetate  
Water bath, heat block, or thermocycler for 37 °C incubation  
Refrigerated microcentrifuge

## 2.4 Protocols

### 2.4.1 Expression and purification of *E. coli* TGT

**2.4.1.1 Overview:** In this protocol, a method for expression and purification of His-tagged *E. coli* TGT is briefly described. While this method has been used several times for the successful purification of *E. coli* TGT, modifications of this general method may be acceptable, including the use of alternative lysis and purification buffers, or alternative lysis techniques. For best results, the use of nuclease free reagents and water is critical, and testing of the resulting purified protein for nuclease contamination is recommended. Purified



*E. coli* TGT should be stored in aliquots at  $-80\text{ }^{\circ}\text{C}$ , as storage at  $-20\text{ }^{\circ}\text{C}$ , even as a glycerol stock, is not recommended.

1. Transform BL21 (DE3) competent cells with the TGT-His plasmid according to the manufacturer's protocol. Protein can be expressed according to standard laboratory procedures; typically, a culture volume of 200 mL is used, and induction is performed at an  $\sim\text{OD}$  of 0.5–0.8 with the addition of IPTG to 1 mM. Expression of TGT is typically carried out for 4 h at  $37\text{ }^{\circ}\text{C}$ .
2. Harvest the bacterial cells by centrifugation at  $10,000 \times g$  for 15 min at  $4\text{ }^{\circ}\text{C}$ . Cell pellets can be stored at  $-20\text{ }^{\circ}\text{C}$  if desired.
3. Prepare the following buffers and solutions for protein purification. Typically, commercial nuclease-free water is used, although MilliQ water can be used if it is tests negative for RNAses.
  - a. 100 mM PMSF
    - Dissolve 174 mg of PMSF in isopropanol to 10 mL. Solution can be stored at  $-20\text{ }^{\circ}\text{C}$ .
  - b. 2 M imidazole (included in HisPur™ Ni-NTA Spin Purification Kit).
  - c.  $2 \times$  TGT lysis buffer, 50 mL (40 mM Tris pH 7.9, 1 M NaCl)
    - 93.7 mg Tris base
    - 193.2 mg Tris HCl
    - 2.92 g NaCl
 Adjust pH to 7.9, total volume of 50 mL.
  - d.  $10 \times$  TGT storage buffer, 50 mL (250 mM HEPES pH 7.3, 20 mM DTT, 10 mM EDTA)
    - 1.26 g HEPES sodium salt
    - 1.83 g HEPES
    - 154.2 mg DTT
    - 1 mL 500 mM EDTA
 Adjust pH to 7.3, total volume of 50 mL. Buffer should be stored at  $4\text{ }^{\circ}\text{C}$  for short-term storage.
  - e. Lysis and purification buffers:

Buffer	Description	Recipe
$1 \times$ lysis buffer, 10 mL	20mM Tris pH 7.9, 500mM NaCl, 100μM PMSF, 10mM imidazole	5mL $2 \times$ lysis buffer 10μL 100mM PMSF 50μL 2M imidazole Adjust to 10mL with H <sub>2</sub> O

Buffer	Description	Recipe
1 × wash buffer, 10 mL	20mM Tris pH 7.9, 500mM NaCl, 100µM PMSF, 25mM imidazole	5mL 2 × lysis buffer 10µL 100mM PMSF 125µL 2M imidazole Adjust to 10mL with H <sub>2</sub> O
1 × dilution buffer, 10 mL	20mM Tris pH 7.9, 500mM NaCl, 100µM PMSF, 350 mM imidazole	5mL 2 × lysis buffer 10µL 100mM PMSF 1.75 mL 2M imidazole Adjust to 10mL with H <sub>2</sub> O
1 × TGT storage buffer, 500 mL	25mM HEPES, pH 7.3, 2 mM DTT, 1 mM EDTA, 100µM PMSF	50mL 10 × TGT storage buffer 500µL 100 mM PMSF Adjust to 500 mL with H <sub>2</sub> O

4. Resuspend bacterial pellet in 1 × lysis buffer. A volume of 2 mL is typically sufficient when 200 mL of culture is used.
5. Lyse cells with a probe sonicator using standard conditions. For example, a Branson Sonifier 450 can be used for 4–5 cycles of 30 s each, with 2 min on ice between cycles, with the output control set to 5 (~20 W output) and a duty cycle of 30%. *Note:* Lysis with a French press also yielded good results (Alexander et al., 2015).
6. Centrifuge lysate at 10,000 × *g* for 30 min at 4 °C to remove cellular debris.
7. Purify TGT-His protein using the buffers described above and the HisPur™ Ni-NTA Spin Purification Kit, according to manufacturer's instructions.
8. Verify purification of TGT-His by SDS-PAGE analysis of fractions. A strong band at a molecular weight of ~43 kDa is expected in the elution fractions.
9. Combine elution fractions containing purified protein; perform dialysis or buffer exchange into 1 × TGT storage buffer.
10. The concentration of the resulting purified protein can be measured using standard laboratory techniques, such as a BCA assay compatible with DTT (i.e. Pierce™ BCA Protein Assay Kit—Reducing Agent Compatible, Thermo Scientific).
11. Purified protein should be stored as single-use aliquots at –80 °C. *E. coli* TGT has been observed to have reduced stability at –20 °C, even if stored as a glycerol stock.

*Tip.* Purified TGT-His often has significant levels of RNase contamination, most likely due to residual *E. coli* RNases. For best results, a second Ni-NTA purification should be performed after buffer exchange, as this tends to reduce the RNase contamination significantly. Commercial RNase detection kits (i.e. RNaseAlert™, Invitrogen) can be used to quantify RNase contamination.

## 2.4.2 Construction of an RNA expression construct with a TGT recognition element

**2.4.2.1 Overview:** In this protocol, a method is presented as an example to demonstrate how a TGT recognition element can be incorporated into an RNA of interest using the pcDNA3.1-(empty)-TAG plasmid, Addgene ID 138209. The method described here appends

a 25-nucleotide TGT recognition element, ECYMH, to human  $\beta$ -actin mRNA. This method relies on restriction cloning to insert the sequence for the RNA of interest into a plasmid containing the TGT recognition element, as well as the elements necessary for transcription by T7 RNA polymerase. Depending on the desired application, other cloning methods may be preferred; for example, a short TGT recognition sequence (ECY-A1, discussed above) can be inserted into an existing vector using site directed mutagenesis.

Primer name	Primer sequence (restriction site in bold, gene-specific sequence capitalized)
NheI-B-actin-fwd	aagctg <b>gctagc</b> ACCGCCGAGACCGCG
BamHI-B-actin-rev	gttag <b>aggatcc</b> CAACTGGTCTCAAGTCAGGTACAGG
B-actin RT	AAGGTGTGCAC <del>T</del> TTTATTCAACT

1. Obtain RT-PCR primers corresponding to the RNA sequence desired. Here, a gene-specific RT primer was designed to reverse transcribe the human  $\beta$ -actin sequence, and PCR primers were designed to amplify the desired sequence and add *NheI* and *BamHI* restriction sites, to facilitate cloning into the pcDNA3.1-(empty)-TAG vector.
2. Set up a reverse transcription reaction to synthesize cDNA corresponding to human  $\beta$ -actin mRNA from isolated or purchased total RNA.

Reagent	Volume ( $\mu$ L)
Ultra-pure water	10.5
Isolated total human RNA, 10ng/ $\mu$ L	1
dNTPs, 10 mM	1
B-actin RT primer, 7.5 mM	2
5 $\times$ RT buffer	4
Murine RNase Inhibitor (40U/ $\mu$ L)	0.5
Maxima RT (200U/ $\mu$ L)	1
Total volume	20

3. Incubate reverse transcription reaction on a thermocycler with the following program:
  - 50 °C, 30 min
  - 85 °C, 5 min
  - 4 °C, hold.
4. Set up a PCR reaction to amplify the cDNA gene and append restriction sites:

Reagent	Volume ( $\mu\text{L}$ )
Ultra-pure water	19
Q5 <sup>®</sup> high fidelity 2 $\times$ master mix	25
NheI-B-actin-fwd, 10 mM	2.5
BamHI-B-actin-rev, 10 mM	2.5
Reverse transcription product	1
Total volume	50

5. Incubate PCR reaction on a thermocycler with the following program:
  - 98 °C, 30 s
  - 35 cycles of:
    - 98 °C, 10 s
    - 70 °C, 30 s (annealing temperature,  $T_a$ , corresponding to the  $\beta$ -actin primers used)
    - 72 °C, 1 min
    - 72 °C, 2 min
    - 4 °C, hold.
6. Purify PCR product using a PCR cleanup kit (i.e. QIAquick PCR cleanup).
7. Set up parallel restriction digests of both the  $\beta$ -actin PCR amplicon and [pcDNA3.1-\(empty\)-TAG](#) vector:

Reagent	Amount
DNA (PCR amplicon OR vector)	2 $\mu\text{g}$
10 $\times$ CutSmart buffer	10 $\mu\text{L}$
NheI-HF	2.5 $\mu\text{L}$
BamHI-HF	2.5 $\mu\text{L}$
Ultra-pure water	To 100 $\mu\text{L}$

8. Incubate restriction digest reactions at 37 °C for 1 h.
9. To restriction digest reaction containing the vector, add 11.5  $\mu\text{L}$  10  $\times$  antarctic phosphatase buffer and 5  $\mu\text{L}$  antarctic phosphatase. Incubate an additional 30 min at 37 °C.
10. Purify the digested DNA samples using a PCR cleanup kit (i.e. QIAquick PCR cleanup).
11. Set up a ligation reaction:

Reagent	Amount
10 × T4 ligase buffer	2µg
Vector (~5.5 kb)	50ng (15fmol)
Insert (~1.8kb)	50ng (45fmol)
T4 ligase	1µL
Ultra-pure water	To 20µL

12. Incubate ligation reaction at room temperature for 10 min.
13. Transform 1–5 µL of ligation reaction into DH5α competent cells, according to manufacturer's protocol.
14. Select using ampicillin and sequence the resulting plasmid to verify gene sequence. The following sequencing primers can be used for pcDNA3.1-(empty)-TAG:

<b>CMV-Forward</b>	<b>CGC AAA TGG GCG GTA GGC GTG</b>
BGH-Reverse	TAG AAG GCA CAG TCG AGG

*Tip.* Run-off transcription can be carried out according to standard procedures using this plasmid backbone. Restriction digestion with XbaI is typically performed, followed by a phenol-chloroform extraction and ethanol precipitation. Plasmids purified with typical Miniprep and Maxiprep procedures are often contaminated with RNase A; therefore, stringent purification is necessary before use in transcription reactions.

### 2.4.3 RNA labeling with RNA-TAG

**2.4.3.1 Overview:** In this protocol, a general method is presented for the labeling of an RNA transcript bearing a TGT recognition element. The use of the extended TGT recognition element, ECYMH, and preQ<sub>1</sub> derivatives functionalized with alkyl linkers are preferred to achieve high labeling efficiencies (>80%).

1. Prepare the following buffers and solutions, which can be stored as aliquots at –20 °C:
  - a. 100 mM DTT, 1 mL
    - Dissolve 15.42 mg DTT with 1 mL of nuclease-free water.
  - b. 10 × TGT reaction buffer, 10 mL (1 M HEPES, pH 7.3, 200 mM MgCl<sub>2</sub>)
    - 1.01 g HEPES sodium salt
    - 1.46 g HEPES
    - 406.6 mg MgCl<sub>2</sub> 6H<sub>2</sub>O

Adjust pH to 7.3, total volume of 10 mL.

- c. Dissolve the purified preQ<sub>1</sub> derivative in nuclease-free water to make a 1000 μM stock solution; DMSO can also be utilized for probes with low solubility. Probe concentration can be verified by measuring absorbance, if desired. Stock solutions of preQ<sub>1</sub> derivatives can be stored at -20 °C for up to 1 year with good results.
- d. Calculate the molarity of your RNA transcript, in μM, using the following equation:

$$\text{RNA concentration}(\mu\text{M}) = \frac{\text{RNA concentration}\left(\frac{\text{ng}}{\mu\text{L}}\right) \times 10^3}{\text{RNA molecular weight}\left(\frac{\text{g}}{\text{mol}}\right)}$$

For example, β-actin-TAG has a molecular weight of 630,595 g/mol, as calculated using OligoCalc (Kibbe, 2007). Therefore, a stock solution of 2240 ng/μL would be 3.55 μM.

- e. Calculate the molarity of your TGT enzyme, in μM, using the following equation: TGT concentration(μM) =  $\frac{\text{protein concentration}\left(\frac{\text{mg}}{\text{mL}}\right) \times 10^6}{43,416}$

For example, a purified protein prep of 1.61 mg/mL would have a concentration of 37.1 μM.

2. Thaw RNA transcript and TGT enzyme on ice. 10 × TGT reaction buffer, 100 mM DTT, and preQ<sub>1</sub> stock solutions can be thawed at room temperature.
3. Set up labeling reactions as follows:

Reagent	Final concentration
10 × TGT reaction buffer	1 × (100 mM HEPES, pH 7.3, 20 mM MgCl <sub>2</sub> )
100mM DTT	5mM
RNA transcript	1μM
TGT enzyme	1μM
preQ <sub>1</sub> -C <sub>6</sub> H <sub>12</sub> -derivative	10μM
RNase inhibitor, murine	1U/μL

Typical reaction volumes are 50 μL, but can be adjusted as necessary; our lab has performed reaction sizes varying from 12.5 to 250 μL.

4. Incubate labeling reactions for 2 h at 37 °C.
5. Purify the RNA through ethanol precipitation by adding 0.1 vol. 3 M NaOAc and 3 volumes of ice-cold, 100% ethanol. Linear polyacrylamide or glycogen may be added as a carrier, if desired.

6. Precipitate RNA at  $-20\text{ }^{\circ}\text{C}$  1 h to overnight.
7. Centrifuge at  $16,000 \times g$  for 30 min at  $4\text{ }^{\circ}\text{C}$  to pellet the RNA.
8. Carefully decant and discard supernatant, taking care not to disturb the RNA pellet.
9. Wash pellet with 75% ice cold ethanol, and centrifuge at  $16,000 \times g$  an additional 5 min at  $4\text{ }^{\circ}\text{C}$ .
10. Discard supernatant and let pellet air dry.
11. Resuspend labeled RNA sample in nuclease-free water for downstream use.

*Tip:* Oligo Clean and Concentrator (Zymo Scientific) can be used as an alternative purification method, if desired.

## 2.5 Precursor techniques

**2.5.1 Synthesis of labeled preQ<sub>1</sub> derivatives**—PreQ<sub>1</sub> hydrochloride is available commercially (Sigma Aldrich) or can be synthesized using previously reported procedures (Klepper, Polborn, & Carell, 2005). Derivatization of preQ<sub>1</sub> has been reported elsewhere (Ehret et al., 2018).

**2.5.2 In vitro transcription with T7 RNA polymerase**—Several methods have been reported for transcription mediated by T7 RNA polymerase (Cazenave & Uhlenbeck, 1994), which have been successfully used in conjunction with RNA-TAG labeling (Alexander et al., 2015). Helpful guides for performing transcription reactions can be found online (Sauer Lab, 2006). Furthermore, commercial kits are available for transcription (i.e. MEGAscript T7 transcription kit, Invitrogen).

**2.5.3 Procedure for validation of TGT enzyme and preQ<sub>1</sub> derivatives**—In order to validate newly synthesized preQ<sub>1</sub> derivatives or batches of purified TGT protein, a gel shift assay with ECY-A1 can be performed. Due to the small size of ECY-A1 (5138.3 g/mol), a characteristic gel shift is observed on denaturing polyacrylamide gels upon the addition of a labeled preQ<sub>1</sub> derivative (Alexander et al., 2015). Typically, labeling reactions are performed in a similar manner as described above for RNA transcripts, using 10  $\mu\text{M}$  ECY-A1, 10  $\mu\text{M}$  TGT, and 20  $\mu\text{M}$  preQ<sub>1</sub> derivative. Ethanol precipitation prior to PAGE analysis improves the resolution of this assay. Common RNA stains, such as GelRed, SYBR green, or methylene blue, can be used; the band intensity of a control sample can be compared to the unshifted, unlabeled band intensity in the labeled sample to evaluate labeling efficiency. Depending on which probe is appended to the RNA, fluorescence of the probe-labeled band may be detected, and can potentially interfere if only the labeled band is analyzed.

## 2.6 Analysis and statistics

Analysis of transcripts labeled with RNA-TAG is dependent on the probe that is being used to label the RNA. For example, degree of labeling with fluorescent reporters has been described using an absorbance assay (Ehret et al., 2018). Another method of analysis

is to run transcripts on a denaturing polyacrylamide gel, and detect fluorescent bands; for example, with a bio-molecular imager (i.e. Typhoon). There are also several available methods for biotin detection, for example streptavidin mediated affinity purification followed by denaturing PAGE (Alexander et al., 2015). An alternative method for biotin detection is northern blotting followed by chemiluminescent detection with biotin-HRP (i.e. Chemiluminescent Nucleic Acid Detection Module Kit, Fisher Scientific).

## 2.7 Troubleshooting and optimization

Problem	Solution
Significant degradation is observed during TGT labeling	TGT enzyme is contaminated with nucleases; test for RNases and subject enzyme to two rounds of Ni-NTA purification. Alternatively, the concentration of RNase inhibitor in the labeling reaction can be increased
Low labeling efficiency is observed	Validate TGT enzyme and preQ <sub>1</sub> derivative using “Procedure for validation of TGT enzyme and preQ <sub>1</sub> derivatives,” described above. Labeling of ECY-A1 should be >90%. Re-express TGT if necessary, minimizing storage time at 4 °C or –20 °C, and storing purified aliquots at –80 °C. Check purity of preQ <sub>1</sub> derivative; certain derivatives may be less well accepted by TGT
	Reaction can be optimized by increasing TGT concentration, preQ <sub>1</sub> derivative concentration, or length of incubation. If a negative control is desired, a G → C mutation to the TGT recognition element can be made (Alexander et al., 2015)

## 3. Summary

Many investigations in RNA biology can benefit from the covalent, site-specific modification of RNA with RNA-TAG. While other RNA labeling methods require end labeling, the installation of long encoded elements, or the use of reactive compounds, RNA-TAG has several advantages. One key advantage is that the site of modification within an RNA of interest can be selected by insertion of a short 17–25 nucleotide stem loop. Furthermore, RNA-TAG leverages a unique nucleobase-probe conjugate that does not react non-specifically with RNA or other biomolecules and is expected to be selective in mammalian systems. In order to implement RNA-TAG labeling, standard techniques for protein expression and purification from *E. coli* can be applied to facilitate the purification of *E. coli* TGT. There are several applicable cloning methods for the insertion of TGT recognition element into a sequence encoding an RNA of interest; however, a straight-forward restriction cloning approach is presented here. Lastly, a general method for RNA labeling with preQ<sub>1</sub> derivatives is presented. These methods have been successfully implemented with a wide variety of preQ<sub>1</sub> probes, including fluorophores, affinity ligands, and click handles, to demonstrate the utility of this approach in numerous applications. The breadth of this approach suggests that this methodology may hold promise for future applications such as RNA interactome studies, RNA imaging, and RNA manipulation in live cells, making even further insights into RNA biology possible.

## Acknowledgment

This work was supported by the National Institutes of Health under award R01 GM123285-01.




## References


- Alexander SC, Busby KN, Cole CM, Zhou CY, & Devaraj NK (2015). Site-specific covalent labeling of RNA by enzymatic transglycosylation. *Journal of the American Chemical Society*, 137(40), 12756–12759. 10.1021/jacs.5b07286. [PubMed: 26393285]
- Biela I, Tidten-Luksch N, Immekus F, Glinca S, Nguyen TXP, Gerber HD, ... Reuter K (2013). Investigation of specificity determinants in bacterial tRNA-guanine transglycosylase reveals queuine, the substrate of its eucaryotic counterpart, as inhibitor. *PLoS One*, 8(5). 10.1371/journal.pone.0064240.
- Cazenave C, & Uhlenbeck OC (1994). RNA template-directed RNA synthesis by T7 RNA polymerase. *Proceedings of the National Academy of Sciences of the United States of America*, 91(15), 6972–6976. 10.1073/pnas.91.15.6972. [PubMed: 7518923]
- Cech TR, & Steitz JA (2014). The noncoding RNA revolution—Trashing old rules to forge new ones.pdf. *Cell*, 157(1), 77–94. 10.1016/j.cell.2014.03.008. [PubMed: 24679528]
- Chen YC, Brooks AF, Goodenough-Lashua DM, Kittendorf JD, Showalter HD, & Garcia GA (2011). Evolution of eukaryal tRNA-guanine transglycosylase: Insight gained from the heterocyclic substrate recognition by the wild-type and mutant human and *Escherichia coli* tRNA-guanine transglycosylases. *Nucleic Acids Research*, 39, 2834–2844. 10.1093/nar/gkq1188. [PubMed: 21131277]
- Chen I, Howarth M, Lin W, & Ting AY (2005). Site-specific labeling of cell surface proteins with biophysical probes using biotin ligase. *Nature Methods*, 2(2), 99–104. 10.1038/nmeth735. [PubMed: 15782206]
- Chin A, & Lécuyer E (2017). RNA localization: Making its way to the center stage. *Biochimica et Biophysica Acta-General Subjects*, 1861(11), 2956–2970. 10.1016/j.bbagen.2017.06.011.
- Cooper TA, Wan L, & Dreyfuss G (2009). RNA and disease. *Cell*, 136(4), 777–793. 10.1016/j.cell.2009.02.011. [PubMed: 19239895]
- Curnow AW, & Garcia GA (1995). tRNA-guanine transglycosylase from *Escherichia coli*: Minimal tRNA structure and sequence requirements for recognition. *Journal of Biological Chemistry*, 270(29), 17264–17267. 10.1074/jbc.270.29.17264. [PubMed: 7615526]
- Curnow A, Kung FL, Koch K, & Garcia G (1993). tRNA-guanine transglycosylase from *Escherichia coli*: Gross tRNA structural requirements for recognition. *Biochemistry*, 32, 5239–5246. [PubMed: 8494901]
- Ehret F, Zhou CY, Alexander SC, Zhang D, & Devaraj NK (2018). Site-specific covalent conjugation of modified mRNA by tRNA guanine transglycosylase. *Molecular Pharmaceutics*, 15(3), 737–742. 10.1021/acs.molpharmaceut.7b00356. [PubMed: 28749687]
- Farkas WR, Jacobson KB, & Katze JR (1984). Substrate and inhibitor specificity of tRNA-guanine ribosyltransferase. *BBA-Gene Structure and Expression*, 781(1–2), 64–75. 10.1016/0167-4781(84)90124-6. [PubMed: 6696916]
- Fergus C, Barnes D, Alqasem MA, & Kelly VP (2015). The queuine micronutrient: Charting a course from microbe to man. *7*, 2897–2929. 10.3390/nu7042897.
- Frye M, Haranda BT, Behm M, & He C (2018). RNA modifications modulate gene expression during development. *Science*, 361(September), 1346–1349. [PubMed: 30262497]
- Gautier A, Juillerat A, Heinis C, Corrêa IR, Kindermann M, Beaufils F, et al. (2008). An engineered protein tag for multiprotein labeling in living cells. *Chemistry and Biology*, 15(2), 128–136. 10.1016/j.chembiol.2008.01.007. [PubMed: 18291317]
- Goodenough-Lashua DAM, & Garcia GA (2003). tRNA-guanine transglycosylase from *E. coli*: A ping-pong kinetic mechanism is consistent with nucleophilic catalysis. *Bioorganic Chemistry*, 31(4), 331–344. 10.1016/S0045-2068(03)00069-5. [PubMed: 12877882]
- Gregson JM, Crain PF, Edmonds CG, Gupta R, Hashizume T, Phillipson DW, et al. (1993). Structure of the archaeal transfer RNA nucleoside G<sup>\*</sup>-15 (2-amino-4,7-dihydro-4-oxo-7-β-D-ribofuranosyl-1H-pyrrolo[2,3-d]pyrimidine-5- carboximidamide (Archaeosine)). *Journal of Biological Chemistry*, 268(14), 10076–10086. [PubMed: 7683667]

- Grosjean H, Edqvist J, Stråby KB, & Giegé R (1996). Enzymatic formation of modified nucleosides in tRNA: Dependence on tRNA architecture. *Journal of Molecular Biology*, 255, 67–85. 10.1006/jmbi.1996.0007. [PubMed: 8568876]
- Ho SH, & Tirrell DA (2016). Chemoenzymatic labeling of proteins for imaging in bacterial cells. *Journal of the American Chemical Society*, 138(46), 15098–15101. 10.1021/jacs.6b07067. [PubMed: 27933886]
- Hoops GC, Townsend LB, & Garcia GA (1995). tRNA-guanine transglycosylase from *Escherichia coli*: Structure-activity studies investigating the role of the aminomethyl substituent of the heterocyclic substrate PreQ1. *Biochemistry*, 34, 15381–15387. [PubMed: 7578154]
- Hoops GC, Park J, Garcia GA, & Townsend LB (1996). The synthesis and determination of acidic ionization constants of certain 5-substituted 2-aminopyrrolo [2,3-d]pyrimidin-4-ones and methylated analogs. *Journal of Heterocyclic Chemistry*, 33(3), 767–781. 10.1002/jhet.5570330341.
- Ishitani R, Nureki O, Fukai S, Kijimoto T, Nameki N, Watanabe M, ... Yokoyama S (2002). Crystal structure of archaeosine tRNA-guanine transglycosylase. *Journal of Molecular Biology*, 318(3), 665–677. 10.1016/S0022-2836(02)00090-6. [PubMed: 12054814]
- Ishitani R, Nureki O, Nameki N, Okada N, Nishimura S, & Yokoyama S (2003). Alternative tertiary structure of tRNA for recognition by a posttranscriptional modification enzyme. *Cell*, 113(3), 383–394. 10.1016/S0092-8674(03)00280-0. [PubMed: 12732145]
- Johannsson S, Neumann P, & Ficner R (2018). Crystal structure of the human tRNA guanine transglycosylase catalytic subunit QTRT1. *Biomolecules*, 8(3), 81. 10.3390/biom8030081. [PubMed: 30149595]
- Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. (2008). Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. *Molecular Therapy*, 16(11), 1833–1840. 10.1038/mt.2008.200. [PubMed: 18797453]
- Kibbe WA (2007). OligoCalc: An online oligonucleotide properties calculator. *Nucleic Acids Research*, 35(Suppl.2), 43–46. 10.1093/nar/gkm234.
- Klepper F, Polborn K, & Carell T (2005). Robust synthesis and crystal-structure analysis of 7-cyano-7-deazaguanine (PreQ0 base) and 7-(aminomethyl)-7-deazaguanine (PreQ1 base). *Helvetica Chimica Acta*, 88(10), 2610–2616. 10.1002/hlca.200590201.
- Li F, Dong J, Hu X, Gong W, Li J, Shen J, ... Wang J (2015). A covalent approach for site-specific RNA labeling in mammalian cells. *Angewandte Chemie-International Edition*, 54(15), 4597–4602. 10.1002/anie.201410433. [PubMed: 25694369]
- Nakanishi S, Ueda T, Hori H, Yamazaki N, Watanabe N, & Okada K (1994). A UGU sequence in the anticodon loop is a minimum requirement for recognition by *Escherichia coli* tRNA-guanine transglycosylase. *Journal of Biological Chemistry*, 269, 32221–32225. [PubMed: 7528209]
- Pathak C, Jaiswal YK, & Vinayak M (2005). Hypomodification of transfer RNA in cancer with respect to queuosine. *RNA Biology*, 2(4), 143–148. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/17114931>. [PubMed: 17114931]
- Richardson RW, & Gumport RI (1983). Biotin and fluorescent labeling of RNA using T4 RNA ligase. *Nucleic Acids Research*, 11(18), 6167–6184. 10.1093/nar/11.18.6167. [PubMed: 6194506]
- Sauer Lab. (2006). In vitro transcription with T7 RNA polymerase. Retrieved from 25 July 2006 website: [https://openwetware.org/wiki/Sauer:In\\_vitro\\_transcription\\_with\\_T7\\_RNA\\_polymerase](https://openwetware.org/wiki/Sauer:In_vitro_transcription_with_T7_RNA_polymerase).
- Schulz D, Holstein JM, & Rentmeister A (2013). A chemo-enzymatic approach for site-specific modification of the RNA cap. *Angewandte Chemie-International Edition*, 52(30), 7874–7878. 10.1002/anie.201302874. [PubMed: 23794451]
- Singh G, Pratt G, Yeo GW, & Moore MJ (2015). The clothes make the mRNA: Past and present trends in mRNP fashion. *Annual Review of Biochemistry*, 84(1), 325–354. 10.1146/annurev-biochem-080111-092106.
- Stengl B, & Klebe G (2007). Novel leads for selective antibiotics against shigellosis by virtual screening, crystallography and synthesis. *Supramolecular Structure and Function*, 9, 209–249.
- Stengl B, Meyer E. a., Heine A, Brenk R, Diederich F, & Klebe G (2007). Crystal structures of tRNA-guanine transglycosylase (TGT) in complex with novel and potent inhibitors unravel pronounced


- induced-fit adaptations and suggest dimer formation upon substrate binding. *Journal of Molecular Biology*, 370, 492–511. 10.1016/j.jmb.2007.04.008. [PubMed: 17524419]
- Stengl B, Reuter K, & Klebe G (2005). Mechanism and substrate specificity of tRNA-guanine transglycosylases (TGTs): tRNA-modifying enzymes from the three different kingdoms of life share a common catalytic mechanism. *ChemBioChem*, 6, 1926–1939. 10.1002/cbic.200500063. [PubMed: 16206323]
- Suzuki T, & Suzuki T (2014). A complete landscape of post-transcriptional modifications in mammalian mitochondrial tRNAs. *Nucleic Acids Research*, 42(11), 7346–7357. 10.1093/nar/gku390. [PubMed: 24831542]
- Todorov KA, & Garcia GA (2006). Role of aspartate 143 in *Escherichia coli* tRNA-guanine transglycosylase: Alteration of heterocyclic substrate specificity. *Biochemistry*, 45(2), 617–625. 10.1021/bi051863d. [PubMed: 16401090]
- Todorov KA, Tan X-J, Nonekowsky ST, Garcia GA, & Carlson HA (2005). The role of aspartic acid 143 in *E. coli* tRNA-guanine transglycosylase: Insights from mutagenesis studies and computational modeling. *Biophysical Journal*, 89(3), 1965–1977. 10.1529/biophysj.105.059576. [PubMed: 15951383]
- Uchida S, Kataoka K, & Itaka K (2015). Screening of mRNA chemical modification to maximize protein expression with reduced immunogenicity. *Pharmaceutics*, 7(3), 137–151. 10.3390/pharmaceutics7030137. [PubMed: 26213960]
- Walden T, Reyniers JP, Hiatt V, & Farkas WR (1982). Yeast cells cannot incorporate queuine into their tRNA. *Proceedings of the Society for Experimental Biology and Medicine*, 170(3), 328–332. 10.3181/00379727-170-41438. [PubMed: 7045884]
- Xie W, Liu X, & Huang RH (2003). Chemical trapping and crystal structure of a catalytic tRNA guanine transglycosylase covalent intermediate. *Nature Structural Biology*, 10(10), 781–788. 10.1038/nsmb0704-678a. [PubMed: 12949492]
- Zhang D, Zhou CY, Busby KN, Alexander SC, & Devaraj NK (2018). Light-activated control of translation by enzymatic covalent mRNA labeling. *Angewandte Chemie-International Edition*, 57(11), 2822–2826. 10.1002/anie.201710917. [PubMed: 29380476]
- Zhou CY, Alexander SC, & Devaraj NK (2017). Fluorescent turn-on probes for wash-free mRNA imaging via covalent site-specific enzymatic labeling. *Chemical Science*, 8(10), 7169–7173. 10.1039/c7sc03150e. [PubMed: 29081948]



**Fig. 1.** Enzymatic RNA labeling with RNA-TAG. Using bacterial TGT, an RNA of interest containing a TGT recognition hairpin is labeled with a preQ<sub>1</sub> derivative.



**Fig. 2.** Nucleobase structures recognized by TGT enzymes in bacteria, eukaryotes, and archaea.



**Fig. 3.** Catalytic mechanism and binding interactions of bacterial TGT with guanine and preQ1. *E. coli* numbering is used. (A) Asp264 acts as a nucleophile to attack the anomeric carbon of ribose 34, breaking the N-C glycosidic linkage. (B) A covalent TGT-RNA covalent intermediate is formed. (C) preQ1 replaces guanine in the binding pocket, assisted by a conformational change of the Leu215/Ala216 peptide bond. (D) N9 of preQ1 acts as a nucleophile to reform a glycosidic bond with ribose 34.

**Table 1**


Kinetics values of select RNA substrates as reported by Curnow and Garcia (1995).

Substrate name (Curnow & Garcia, 1995)	Stem loop sequence	$K_m$ , $\mu\text{M}$	$V_{\max}$ , $\mu\text{M}^{-1} \text{mg}^{-1}$	$V_{\max}/K_m$ , $\text{s}^{-1} \text{mg}^{-1}$
ECY2 (unmodified tRNA <sup>Tyr</sup> )	...GCAGACUGUAAAUCUGC...	2.0	3.0	1.5
ECY-A1	GCAGACUGUAAAUCUGC	13.3	0.48	0.04
ECYMH	GGGAGCAGACUGUAAAUCUGCUCCC	6.9	2.2	0.3
SCDMH	GGCGGCGCUUGUCGCGUGCCGCC	11.4	2.7	0.24
SCDMH-U33C	GGCGGCGCUUGUCGCGUGCCGCC	22.4	0.06	0.003
SCDMH-G34A	GGCGGCGCUUAUCGCGUGCCGCC	N.D.	N.D.	N.D.
SCDMH-U35C	GGCGGCGCUUGCCGCGUGCCGCC	N.D.	N.D.	N.D.

N.D. = no detectable activity.

**Table 2**

Kinetic parameters of various nucleobase substrates.

Compound	$K_m$ , $\mu\text{M}$	$k_{\text{cat}}^a$ ( $\times 10^{-3}$ ) $\text{s}^{-1}$	$k_{\text{cat}}/K_m^a$ ( $\times 10^{-3}$ ) $\text{s}^{-1} \mu\text{M}^{-1}$	Ref.
Guanine	2.2	61 <sup>a</sup>	28 <sup>a</sup>	Hoops et al. (1995)
				
-CH <sub>2</sub> NH <sub>2</sub> (preQ <sub>1</sub> )	0.39	45 <sup>a</sup>	115 <sup>a</sup>	Hoops et al. (1995)
-CN (preQ <sub>0</sub> )	2.35	72 <sup>a</sup>	31 <sup>a</sup>	Hoops et al. (1995)
-CH <sub>2</sub> OH	23.0	45 <sup>a</sup>	2.0 <sup>a</sup>	Hoops et al. (1995)
-H	172	45 <sup>a</sup>	0.3 <sup>a</sup>	Hoops et al. (1995)
-CH <sub>3</sub>	255	45 <sup>a</sup>	0.2 <sup>a</sup>	Hoops et al. (1995)
-CH <sub>2</sub> OCH <sub>3</sub>	57	47 <sup>a</sup>	0.8 <sup>a</sup>	Hoops et al. (1995)
-CH <sub>2</sub> N(CH <sub>3</sub> ) <sub>2</sub>	75	43 <sup>a</sup>	0.6 <sup>a</sup>	Hoops et al. (1995)
-CONH <sub>2</sub>	26	69 <sup>a</sup>	2.7 <sup>a</sup>	Hoops et al. (1995)
-CO <sub>2</sub> CH <sub>3</sub>	87	73 <sup>a</sup>	0.8 <sup>a</sup>	Hoops et al. (1995)
-COCH <sub>3</sub>	26	73 <sup>a</sup>	2.8 <sup>a</sup>	Hoops et al. (1995)
-CHO	22	73 <sup>a</sup>	3.3 <sup>a</sup>	Hoops et al. (1995)
-CO <sub>2</sub> H	126	21 <sup>a</sup>	0.2 <sup>a</sup>	Hoops et al. (1995)
-(PEG) <sub>3</sub> -thiazole orange	9.8	1.6	0.2	Alexander et al. (2015)
-C <sub>6</sub> H <sub>12</sub> -thiazole orange derivative	1.6	26.7	16.7	Zhou et al. (2017)

<sup>a</sup> $k_{\text{cat}}$  were calculated from reported  $V_{\text{max}}$  values using the reported enzyme concentration (50 nM), and reaction volume (400  $\mu\text{L}$ ) (Hoops et al., 1995).



**Table 3**Kinetic parameters for *E. coli* and human TGTs with heterocyclic substrates.

	$K_m$ , $\mu\text{M}$	$k_{\text{cat}}$ ( $\times 10^{-3}$ ) $\text{s}^{-1}$	$k_{\text{cat}}/K_m$ ( $\times 10^{-3}$ ) $\text{s}^{-1} \mu\text{M}^{-1}$
Guanine			
<i>E. coli</i>	0.35	6.29	18.0
Human	0.41	5.86	14.2
PreQ <sub>1</sub>			
<i>E. coli</i>	0.05	9.57	191
Human	132	8.23	0.062
Queuine			
<i>E. coli</i>	N.D.	N.D.	N.D.
Human	0.26	8.22	31.6

Data from Chen, Y. C., Brooks, A. F., Goodenough-Lashua, D. M., Kittendorf, J. D., Showalter, H. D., & Garcia, G. A. (2011). Evolution of eukaryal tRNA-guanine transglycosylase: Insight gained from the heterocyclic substrate recognition by the wild-type and mutant human and *Escherichia coli* tRNA-guanine transglycosylases. *Nucleic Acids Research*, *39*, 2834–2844. <https://doi.org/10.1093/nar/gkq1188>.